Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQFD42)

Drug Name

Leriglitazone Drug Info

Synonyms

Hydroxypioglitazone; 146062-44-4; Leriglitazone; Hydroxy Pioglitazone (M-IV); MIN-102; Leriglitazone [USAN]; K824X25AYA; CHEBI:82937; UNII-K824X25AYA; 2,4-Thiazolidinedione, 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-; 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; WHO 10868; Hydroxy Pioglitazone-D5 (Major) (M-IV); 2,4-Thiazolidinedione, 5-((4-(2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-; 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; 1-Hydroxypioglitazone; Pioglitazone, hydroxy; LERIGLITAZONE [INN]; Leriglitazone (USAN/INN); CHEMBL1267; SCHEMBL4098326; DTXSID30399914; OXVFDZYQLGRLCD-UHFFFAOYSA-N; BDBM50530214; ZINC01482947; AKOS015856344; DB15021; 5-[[4-[2-[5-(1-Hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione; HY-117727; CS-0067030; FT-0643388; D11603; A1-01710; J-008187; Q27156475; 5-(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione; ALL-AMBO-5-((4-(2-(5-(1-HYDROXYETHYL)PYRIDIN-2-YL)ETHOXY)PHENYL)METHYL)-1,3-THIAZOLE-2,4(3H,5H)-DIONE

Indication

Disease Entry	ICD 11	Status	REF
Cerebral X-linked adrenoleukodystrophy	5C57.1	Phase 3	[1]

Cross-matching ID

PubChem CID: 4147757
ChEBI ID: CHEMBL1267
TTD Drug ID: DMQFD42

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)	TTZMAO3	PPARG_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)	DTT	PPARG	5.576	6.977	5.736	5.758

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Cerebral X-linked adrenoleukodystrophy

ICD Disease Classification

5C57.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)	DTT	PPARG	2.41E-01	-0.06	-0.25

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT05819866) A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Minoryx Therapeutics